Vibegron is a novel small molecule β 3 adrenergic receptor agonist.

1、 Drug name

Common name: vibegron

Product Name: GEMTESA ®

2、 Indications

Used to treat adult overactive bladder (OAB) accompanied by symptoms of urgency urinary incontinence, urgency, and frequency of urination.

3、 Specifications

Specification: 75mg tablets

4、 Main components

Active ingredient: Vibergron 75mg.

5、 Usage and dosage

Recommended dosage: once daily, 75mg each time

6、 Dose adjustment

Mild to moderate renal insufficiency patients do not require dose adjustment.

Patients with end-stage renal disease (with or without hemodialysis) are not recommended to use it.

Mild to moderate liver dysfunction patients do not require dose adjustment.

Not recommended for patients with severe liver dysfunction.

7、 Medication precautions

It can be taken before and after meals.

Food does not affect drug efficacy.

Omission handling: Not clearly stated, it is recommended to follow medical advice.

Vomiting treatment: Not clearly stated, it is recommended to follow medical advice.

8、 Medication for special populations

Pregnant women: No human data available, need to weigh the pros and cons.

Breastfeeding period: Medications may enter breast milk, it is recommended to consult a doctor.

Children: Safety and effectiveness have not yet been established.

Elderly patients: There is no significant difference compared to younger patients.

9、 Adverse reactions

Common adverse reactions (≥ 2%) include:

Headache (4.0%).

Urinary tract infection (2.8%).

Nasopharyngitis (2.8%).

Diarrhea (2.2%).

Disgusting (2.2%).

Upper respiratory tract infection (2.0%)

10、 Contraindications

Individuals with a history of allergies to Veblende or any of its ingredients are prohibited from using it.

11、 Drug interactions

Digoxin: Co administration may increase the blood concentration of digoxin, and the dosage needs to be monitored and adjusted.

12、 Storage method

Storage temperature: 20 ° C-25 ° C (68 ° F-77 ° F).

Allow short-term storage at 15 ° C-30 ° C (59 ° F-86 ° F).

Keep out of reach of children.

13、 Special Warning

The patients who may cause urinary retention, especially those with bladder outlet obstruction or who use muscarine antagonists at the same time, should be closely monitored.

vibegroninformation